CN114585622B - 作为nsd2抑制剂和抗癌剂的哌啶基-甲基-嘌呤胺 - Google Patents

作为nsd2抑制剂和抗癌剂的哌啶基-甲基-嘌呤胺 Download PDF

Info

Publication number
CN114585622B
CN114585622B CN202080069611.5A CN202080069611A CN114585622B CN 114585622 B CN114585622 B CN 114585622B CN 202080069611 A CN202080069611 A CN 202080069611A CN 114585622 B CN114585622 B CN 114585622B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
alkyl
mixture
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080069611.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN114585622A (zh
Inventor
邓海兵
刘金镖
欧阳孔德
王策
肖启桃
寻国良
曾海强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN114585622A publication Critical patent/CN114585622A/zh
Application granted granted Critical
Publication of CN114585622B publication Critical patent/CN114585622B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080069611.5A 2019-08-14 2020-08-12 作为nsd2抑制剂和抗癌剂的哌啶基-甲基-嘌呤胺 Active CN114585622B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/100542 2019-08-14
PCT/CN2019/100542 WO2021026803A1 (en) 2019-08-14 2019-08-14 Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
PCT/IB2020/057602 WO2021028854A1 (en) 2019-08-14 2020-08-12 Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents

Publications (2)

Publication Number Publication Date
CN114585622A CN114585622A (zh) 2022-06-03
CN114585622B true CN114585622B (zh) 2024-08-09

Family

ID=72145436

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080069611.5A Active CN114585622B (zh) 2019-08-14 2020-08-12 作为nsd2抑制剂和抗癌剂的哌啶基-甲基-嘌呤胺

Country Status (20)

Country Link
US (3) US11420970B1 (https=)
EP (2) EP4013755B1 (https=)
JP (2) JP7638960B2 (https=)
KR (1) KR102946008B1 (https=)
CN (1) CN114585622B (https=)
AU (1) AU2020328919A1 (https=)
BR (1) BR112022002520A2 (https=)
CO (1) CO2022002804A2 (https=)
DK (1) DK4013755T3 (https=)
EC (1) ECSP22019360A (https=)
ES (1) ES3023540T3 (https=)
FI (1) FI4013755T3 (https=)
IL (2) IL289754B2 (https=)
MX (1) MX2022001784A (https=)
MY (1) MY209614A (https=)
PH (1) PH12022550343A1 (https=)
PL (1) PL4013755T3 (https=)
PT (1) PT4013755T (https=)
WO (2) WO2021026803A1 (https=)
ZA (1) ZA202200519B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021026803A1 (en) * 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
DK4013756T3 (da) * 2019-09-20 2024-05-27 Novartis Ag MLL1-inhibitorer og anticancermidler
JP2025504379A (ja) * 2022-01-05 2025-02-12 ケイ３６・セラピューティクス・インコーポレイテッド 重水素濃縮ピペリジニル－メチル－プリンアミン及び関連化合物、ならびに疾患及び状態の治療におけるそれらの使用
IL314895A (en) * 2022-02-16 2024-10-01 Duke Street Bio Ltd Pharmaceutical compound
WO2023225150A1 (en) * 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
US20250326752A1 (en) * 2022-05-18 2025-10-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
AU2023273656A1 (en) * 2022-05-18 2024-11-28 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine d-tartaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225144A1 (en) * 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023230038A1 (en) * 2022-05-23 2023-11-30 K36 Therapeutics, Inc. Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions
US20250361235A1 (en) * 2022-05-23 2025-11-27 K36 Therapeutics, Inc. Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions
WO2024073283A1 (en) * 2022-09-26 2024-04-04 Board Of Regents, The University Of Texas System Heterocycles as modulators of nsd activity
JP2025530501A (ja) * 2022-09-26 2025-09-11 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ｎｓｄ活性の修飾物質としての複素環
KR20250129690A (ko) * 2022-12-12 2025-08-29 케이36 테라퓨틱스, 인크. 피페리딘일-메틸-푸린 아민을 함유하는 약학적 조성물과 질환 및 병태 치료에서 이의 용도
WO2025106786A1 (en) * 2023-11-17 2025-05-22 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
CN117720550A (zh) * 2023-12-14 2024-03-19 深圳市华先医药科技有限公司 (s)-3-甲基-4-氧代-2-氧杂-8-氮杂螺[4.5]癸烷-8-甲酸叔丁酯合成方法
CN117843641B (zh) * 2023-12-28 2025-04-25 和径医药科技（上海）有限公司 Nsd3抑制剂及其制备方法和应用
WO2025147514A1 (en) * 2024-01-02 2025-07-10 K36 Therapeutics, Inc. Piperidinyl-methyl-purineamine nsd2 inhibitor therapeutic methods and compositions for treating cancer
CN118459395A (zh) * 2024-05-10 2024-08-09 南通大学 一种5-(叔丁氧羰基氨基)哌啶-3-羧酸甲酯的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108853110A (zh) * 2018-08-24 2018-11-23 江苏理工学院 一种化合物a8作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN109223794A (zh) * 2018-08-24 2019-01-18 江苏理工学院 一种化合物c6作为组蛋白甲基转移酶nsd3活性抑制剂及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157465B2 (en) 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
US7332486B2 (en) * 2002-08-08 2008-02-19 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
MXPA05003193A (es) * 2002-09-27 2005-06-08 Sumitomo Pharma Compuesto de adenina novedoso y uso del mismo.
JP2004137157A (ja) * 2002-10-16 2004-05-13 Sumitomo Pharmaceut Co Ltd 新規アデニン誘導体を有効成分として含有する医薬
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
JP5694345B2 (ja) * 2009-10-22 2015-04-01 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体の調節因子
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
WO2019196918A1 (zh) 2018-04-13 2019-10-17 罗欣药业(上海)有限公司 五元杂环并嘧啶类化合物、药物组合物及用途
WO2021026803A1 (en) * 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
JP2025504379A (ja) 2022-01-05 2025-02-12 ケイ３６・セラピューティクス・インコーポレイテッド 重水素濃縮ピペリジニル－メチル－プリンアミン及び関連化合物、ならびに疾患及び状態の治療におけるそれらの使用
AU2023273656A1 (en) 2022-05-18 2024-11-28 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine d-tartaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225144A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
US20250326752A1 (en) 2022-05-18 2025-10-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225150A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108853110A (zh) * 2018-08-24 2018-11-23 江苏理工学院 一种化合物a8作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN109223794A (zh) * 2018-08-24 2019-01-18 江苏理工学院 一种化合物c6作为组蛋白甲基转移酶nsd3活性抑制剂及其应用

Also Published As

Publication number Publication date
BR112022002520A2 (pt) 2022-05-10
KR20220047330A (ko) 2022-04-15
US20230002388A1 (en) 2023-01-05
AU2020328919A1 (en) 2022-02-17
EP4013755A1 (en) 2022-06-22
EP4013755B1 (en) 2025-01-08
IL289754A (en) 2022-03-01
KR102946008B1 (ko) 2026-04-01
CN114585622A (zh) 2022-06-03
CA3144542A1 (en) 2021-02-18
US11420970B1 (en) 2022-08-23
IL320143A (en) 2025-06-01
DK4013755T3 (da) 2025-03-31
ECSP22019360A (es) 2022-04-29
MY209614A (en) 2025-07-24
IL289754B2 (en) 2025-09-01
PH12022550343A1 (en) 2023-03-13
WO2021026803A1 (en) 2021-02-18
US12312353B2 (en) 2025-05-27
JP2022544946A (ja) 2022-10-24
JP2025081505A (ja) 2025-05-27
MX2022001784A (es) 2022-04-18
CO2022002804A2 (es) 2022-04-08
ES3023540T3 (en) 2025-06-02
JP7638960B2 (ja) 2025-03-04
FI4013755T3 (fi) 2025-04-02
PL4013755T3 (pl) 2025-05-12
WO2021028854A1 (en) 2021-02-18
IL289754B1 (en) 2025-05-01
PT4013755T (pt) 2025-05-02
US20250276971A1 (en) 2025-09-04
EP4559915A1 (en) 2025-05-28
ZA202200519B (en) 2024-08-28

Similar Documents

Publication Publication Date Title
CN114585622B (zh) 作为nsd2抑制剂和抗癌剂的哌啶基-甲基-嘌呤胺
TWI869519B (zh) Sos1抑制劑
AU2015257456B2 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
AU2021289169B2 (en) Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
JP2025515285A (ja) 大環状複素環及びその使用
JP2020525471A (ja) Ｎｉｋ阻害剤としての新規の置換アザインドリン誘導体
JP7261752B2 (ja) 新規キノリノン化合物
KR102779693B1 (ko) Mll1 억제제 및 항암제
TW202417435A (zh) 用於治療之parp14之靶向蛋白質降解
CA3213823A1 (en) Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
CN114929705A (zh) Mll1抑制剂及抗癌剂
CA3144542C (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
HK40075573B (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
HK40075573A (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
EA047083B1 (ru) Пиперидинил-метил-пуринамины в качестве ингибиторов nsd2 и противораковых средств
TW202545531A (zh) 氮—喹唑啉化合物之使用方法
CN118369317A (zh) 黑皮质素4受体拮抗剂及其用途
TW202208379A (zh) 新穎的巨環lrrk2激酶抑制劑
HK1226736B (zh) 2，6-取代嘌呤衍生物及其在治疗增殖性疾病中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant